Argenx's Myositis Win Proves the Platform. It Doesn't Make the Stock Cheap.

Argenx's Myositis Win Proves the Platform. It Doesn't Make the Stock Cheap.

The readout that hit in mid-August — positive Phase 3 data for VYVGART Hytrulo (efgartigimod) in autoimmune myositis — sent argenx (NASDAQ: ARGX) to the top of its fifty-two-week range. The shares opened nearly 9% higher the morning the data landed and kept climbing, up more than 20% in five sessions. On paper that looks like the classic binary-catalyst trade: the drug worked, the stock jumped, on to the next readout. My process reads it differently. A binary data event tells you the pipeline advanced; it tells you almost nothing about whether today's price is the right price. For argenx, the real story is the report card behind the headline — and that report card was already near the top of large-cap biotech before ALKIVIA ever printed.

What the trial actually proved

Start with the science, because it's genuinely good. ALKIVIA met its primary endpoint — mean Total Improvement Score (TIS) at 52 weeks in the combined population of immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patients — with p=0.0011. TIS is worth one plain-English sentence: it's a composite that weighs muscle strength, physical function, and disease activity, the field's standard way of judging whether a patient actually got better rather than just hitting a lab target.

argenx bills ALKIVIA as the first Phase 3 study in these diseases to show statistically significant and clinically meaningful benefit, with improvements showing up early and persisting across the full 52 weeks and in both disease subtypes. Extension data amplified the case: 37.5% of continuously treated patients maintained their major week-24 improvement out to week 52 — durability that matters in a chronic autoimmune disease. The company's partner in Greater China, Zai Lab, co-announced the result, a reminder that an approved myositis drug now has a global launch path waiting before the label even exists.

The drug itself explains the whole bull case. Efgartigimod blocks FcRn, the receptor that recycles antibodies through the bloodstream, so it strips out the disease-driving autoantibodies — and that is why one mechanism can work across generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), and now myositis. It treats the class of disease, not the label.

Here is where I slow down, because the factor question is different from the headline question. Myositis is real, serious, and underserved — autoimmune inflammation that leaves skeletal muscle weak and patients disabled. But as a market, it is small: by one market-research estimate, the entire leading-market drug market for inflammatory myositis is roughly half a billion dollars. argenx just reported $1.5 billion in product sales in a single quarter. Do that relative math and the readout's commercial meaning is plain. ALKIVIA is a platform-validation event and a topline story, not a near-term revenue inflector. It earns its headline by confirming that efgartigimod converts across autoimmune muscle disease; it does not, on its own, justify paying more for the multiple.

The five-factor report card

This is where the system earns its keep. Scored against the factor framework I run, argenx looks like a leader on four of five factors and the most expensive name in its peer group on the fifth.

• Growth: strong. Revenue is up about 70% year over year on the fundamental screen, and the company's own numbers back it: $1.5 billion in second-quarter product sales, up 60% from a year earlier and 17% sequentially. The franchise went from a niche myasthenia gravis drug to $4.2 billion in full-year 2025 product sales, with seronegative gMG launched this year on top of the core indications — the addressable pool keeps getting broader.
• Profitability: strong. Gross margin around 90%, operating margin near 30%, return on invested capital above 20%. For a company that used to get filed under pipeline-and-prayer, those are franchise-cash-generator numbers.
• Safety: strong. More than $3.5 billion in cash and no net debt, with a quick ratio near 490% on the screen. The balance sheet is not the risk here.
• Momentum: strong, but extended. The stock is up 21% in five days, trades above both its 50-day and 200-day averages, and its 14-day RSI is around 73 — textbook overbought territory. Momentum confirms the timing of the trade; it does not make the trade.
• Valuation: the drag. At roughly 12x trailing sales and 36x EV/EBITDA, argenx is the premium multiple in the large-cap biotech set — Biogen trades near 3x sales, Regeneron near 5.5x, Vertex near 11x, Alnylam near 6x. Most telling is the forward P/E: near 78x against a trailing 38x. That inverted profile means the market is paying up for next year's estimated earnings rather than this year's, and a multiple with no cushion has no room for those estimates to disappoint.

For the record, the external aggregate agrees with the factor stack: AInvest's aggregate signal currently labels argenx a Buy, with a composite analysis score of 4.63. It is a cross-check, not a conclusion. My read, in plain English, is narrower and more honest: a top-quartile growth, profitability, and safety profile carrying a valuation that has clearly caught up to the story.

What the discipline says to do

The hardest part of a winner that keeps winning is knowing what to do with it. This is a "let the winner run, but never remove discipline" situation. Holding argenx because the factor stack is intact is defensible; piling into a 21% pop that left the RSI overbought and the forward multiple near 78x is a different decision entirely — that is paying the momentum markup on top of the valuation markup. Two things would change my rating: forward estimates stalling, since the multiple leaves no cushion, or the next pipeline readouts stumbling from an extended base. argenx said at its July report that it entered the second half with two registrational study readouts expected before year-end — ALKIVIA was the first, and management has said four of its molecules will sit in Phase 3 by the end of 2026, including the next-generation candidate adimanebart (ARGX-119). More binary event risk is coming at exactly the moment the tape is most extended, and the shares already wobbled around a myositis research day in June this year — a reminder that this stock does not move in a straight line.

Positioning-wise, argenx belongs in the quality-growth sleeve of a balanced book — the aggressive end of a barbell, where you accept pipeline binary risk in exchange for 60%-plus top-line growth, and you balance it against cash-flow and dividend businesses that compound without needing a readout. The myositis win does not change that assignment; it confirms it. What the rally since August 17 really tells you is that the market has caught up to what the factor stack already said — and when the market agrees with the factors, the remaining edge belongs to the patient holder, not the chaser.